📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. (2023)

First Author: Harrison CN

Attributed to: Joint Wellcome and MRC Centre, ‘Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute’ funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.22.01935

PubMed Identifier: 37126762

Publication URI: http://europepmc.org/abstract/MED/37126762

Type: Journal Article/Review

Volume: 41

Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Issue: 19

ISSN: 0732-183X